EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 / Numéro 11 (Novembre 2023) Med Sci (Paris), 39 11 (2023) 889-892 Références
Numéro
Med Sci (Paris)
Volume 39, Numéro 11, Novembre 2023
Nos jeunes pousses ont du talent !
Page(s) 889 - 892
Section Partenariat médecine/sciences - Écoles doctorales - Masters
DOI https://doi.org/10.1051/medsci/2023126
Publié en ligne 29 novembre 2023
  1. The International Agency for Research on Cancer (IARC). Global Cancer Observatory, 2020. [Google Scholar]
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2018 ; 68 : 7–30. [CrossRef] [PubMed] [Google Scholar]
  3. The Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 2015 ; 161 : 1681–1696. [CrossRef] [PubMed] [Google Scholar]
  4. Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 2014 ; 13 : 928–942. [CrossRef] [PubMed] [Google Scholar]
  5. Yu C, Liu X, Yang J et al. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Front Immunol 2019 ; 10 : 990. [CrossRef] [PubMed] [Google Scholar]
  6. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012 ; 367 : 1694–1703. [CrossRef] [PubMed] [Google Scholar]
  7. Long GV, Weber JS, Infante JR, et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol 2016 ; 34 : 871–878. [CrossRef] [PubMed] [Google Scholar]
  8. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017 ; 14 : 463–482. [PubMed] [Google Scholar]
  9. Kalaora S, Nagler A, Wargo JA, Samuels Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer 2022; 22 : 195–207. [CrossRef] [PubMed] [Google Scholar]
  10. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006, 203 ; 7 : 1651–1656. [CrossRef] [PubMed] [Google Scholar]
  11. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013 ; 19 : 1225–1231. [CrossRef] [PubMed] [Google Scholar]
  12. Reddy SM, Reuben A, Wargo JA. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Curr Oncol Rep 2016 ; 18 : 42. [CrossRef] [PubMed] [Google Scholar]
  13. Ribas A, Butler M, Lutzky J, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. JCO 2015 ; 15 : 3003. [CrossRef] [Google Scholar]
  14. Haas L, Elewaut A, Gerard CL, et al. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nat Cancer 2021; 2 : 7. [Google Scholar]
  15. Long GV, Carlino MS, Au-Yeung G, et al. NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy. JCO 2022; 40 : 9503. [CrossRef] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.